Gossamer Bio, Inc. (GOSS) vs MiNK Therapeutics, Inc. (INKT)
A side-by-side comparison of Gossamer Bio, Inc. and MiNK Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GOSS
Gossamer Bio, Inc.
$10.73HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
INKT
MiNK Therapeutics, Inc.
$11.75HealthcareDelayed quote: Oct 6, 2026, 11:54 AM EDT
Total return — GOSS vs INKT
growth of $100 · dividends reinvested · last 5yGOSS -99.0% (-60.3%/yr)INKT -89.8% (-36.7%/yr)INKT compounded faster over this window
Log scale — wide-divergence pair
GOSS INKT
GOSS vs INKT: by the numbers
- •GOSS is the larger company ($66M vs $59M market cap).
- •Both run net losses; INKT's is the smaller (0.00% vs -235.00% net margin).
Metrics side by side
Valuation
| Metric | GOSS | INKT |
|---|---|---|
| P/S ratio | 1.23 | N/A |
Profitability
| Metric | GOSS | INKT |
|---|---|---|
| Gross margin | 99.56% | 0.00% |
| Operating margin | -336.81% | 0.00% |
| Net margin | -235.00% | 0.00% |
| ROIC | N/A | -604.20% |
Growth (annualized)
| Metric | GOSS | INKT |
|---|---|---|
| Total return CAGR (5Y) | -59.51% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.